Albert S. Yu

4.2k total citations · 2 hit papers
48 papers, 3.2k citations indexed

About

Albert S. Yu is a scholar working on Molecular Biology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Albert S. Yu has authored 48 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 17 papers in Genetics and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Albert S. Yu's work include Chronic Lymphocytic Leukemia Research (16 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Ion Channels and Receptors (6 papers). Albert S. Yu is often cited by papers focused on Chronic Lymphocytic Leukemia Research (16 papers), PI3K/AKT/mTOR signaling in cancer (6 papers) and Ion Channels and Receptors (6 papers). Albert S. Yu collaborates with scholars based in United States, Japan and Switzerland. Albert S. Yu's co-authors include Ian W. Flinn, Steven Coutré, Langdon L. Miller, Brian J. Lannutti, Anthony Valdini, Leo M. Sreebny, Nina D. Wagner‐Johnston, Richard R. Furman, Brad S. Kahl and Sissy Peterman and has published in prestigious journals such as Neuron, Journal of Clinical Oncology and Blood.

In The Last Decade

Albert S. Yu

45 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

2014 465 citations Steven Coutré, Ian W. Flinn et al. Blood profile →
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

2011 442 citations Julia Hoellenriegel, Sarah Meadows et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Albert S. Yu United States	26	1.6k	1.2k	993	616	413	48	3.2k
Changli Wei United States	27	580 0.4×	663 0.6×	1.2k 1.2×	651 1.1×	276 0.7×	61	4.2k
Jacek Szechiński Poland	20	934 0.6×	679 0.6×	579 0.6×	1.5k 2.4×	1.1k 2.8×	58	5.0k
Dávid Ma Australia	21	603 0.4×	1.3k 1.1×	472 0.5×	293 0.5×	585 1.4×	69	2.9k
Christoph Renné Germany	20	472 0.3×	551 0.5×	508 0.5×	738 1.2×	314 0.8×	29	2.1k
Elizabeth Trehu United States	16	491 0.3×	657 0.5×	914 0.9×	529 0.9×	501 1.2×	33	2.3k
Daniela Rottoli Italy	32	965 0.6×	357 0.3×	1.5k 1.6×	492 0.8×	179 0.4×	47	4.1k
Giuseppe A. Palumbo Italy	36	1.1k 0.7×	500 0.4×	1.6k 1.6×	1.1k 1.8×	1.5k 3.5×	216	4.2k
Ramon Bonegio United States	24	237 0.1×	843 0.7×	1.1k 1.1×	941 1.5×	252 0.6×	42	3.6k
Stefania Loffredo Italy	34	567 0.4×	290 0.2×	873 0.9×	1.8k 2.9×	143 0.3×	99	3.6k
Marieke J. H. Coenen Netherlands	34	249 0.2×	410 0.3×	1.1k 1.1×	844 1.4×	217 0.5×	131	3.2k

Countries citing papers authored by Albert S. Yu

Since Specialization

Citations

This map shows the geographic impact of Albert S. Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert S. Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert S. Yu more than expected).

Fields of papers citing papers by Albert S. Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert S. Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert S. Yu. The network helps show where Albert S. Yu may publish in the future.

Co-authorship network of co-authors of Albert S. Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Albert S. Yu. A scholar is included among the top collaborators of Albert S. Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert S. Yu. Albert S. Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zong, Pengyu, Jianlin Feng, Zhichao Yue, et al.. (2025). TRPM2 overactivation drives hyperlipidemia-induced dysfunction of myeloid cells and neurovascular units. Cell Reports Medicine. 6(3). 101998–101998.

Yu, Albert S., et al.. (2025). Leveraging IndoBERT and DistilBERT for Indonesian emotion classification in e-commerce reviews. Procedia Computer Science. 269. 321–330.

Huang, Cheng‐Wei, Albert S. Yu, Hui Zhou, et al.. (2024). Comparative Effectiveness of Bisoprolol, Carvedilol, and Metoprolol Succinate in Patients with Heart Failure and CKD. Clinical Journal of the American Society of Nephrology. 20(1). 136–138.

Yu, Albert S., et al.. (2023). All-Cause and Cardiovascular-Related Mortality in CKD Patients With and Without Heart Failure: A Population-Based Cohort Study in Kaiser Permanente Southern California. Kidney Medicine. 5(5). 100624–100624. 23 indexed citations

Zong, Pengyu, Jianlin Feng, Zhichao Yue, et al.. (2022). TRPM2 deficiency in mice protects against atherosclerosis by inhibiting TRPM2–CD36 inflammatory axis in macrophages. Nature Cardiovascular Research. 1(4). 344–360. 35 indexed citations

Huang, Cheng‐Wei, Joonsoo Park, Albert S. Yu, et al.. (2022). Disease-Specific Factors Associated with Readmissions or Mortality After Hospital Discharge in COVID-19 Patients: a Retrospective Cohort Study. Journal of General Internal Medicine. 37(15). 3973–3978. 7 indexed citations

Zong, Pengyu, Jianlin Feng, Zhichao Yue, et al.. (2022). Functional coupling of TRPM2 and extrasynaptic NMDARs exacerbates excitotoxicity in ischemic brain injury. Neuron. 110(12). 1944–1958.e8. 67 indexed citations

Huang, Cheng‐Wei, et al.. (2022). Association Between Dexamethasone Treatment After Hospital Discharge for Patients With COVID-19 Infection and Rates of Hospital Readmission and Mortality. JAMA Network Open. 5(3). e221455–e221455. 9 indexed citations

Singh, Avi, et al.. (2021). Parrot: Data-Driven Behavioral Priors for Reinforcement Learning. International Conference on Learning Representations. 3 indexed citations

10.

Yu, Albert S., et al.. (2021). Statin use and survival among ESKD patients hospitalized with sepsis. Clinical Kidney Journal. 14(6). 1710–1712. 3 indexed citations

11.

Zeng, Hui, Min Guo, Ting Zhou, et al.. (2016). An Isogenic Human ESC Platform for Functional Evaluation of Genome-wide-Association-Study-Identified Diabetes Genes and Drug Discovery. Cell stem cell. 19(3). 326–340. 84 indexed citations

12.

Horak, Friedrich, Kamal D. Puri, Bart Steiner, et al.. (2016). Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis. Journal of Allergy and Clinical Immunology. 137(6). 1733–1741. 27 indexed citations

13.

Tsujikawa, Hiroto, Albert S. Yu, Jia Xie, et al.. (2015). Identification of key amino acid residues responsible for internal and external pH sensitivity of Orai1/STIM1 channels. Scientific Reports. 5(1). 16747–16747. 28 indexed citations

14.

Hoellenriegel, Julia, Sarah Meadows, Mariela Sivina, et al.. (2011). The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 118(13). 3603–3612. 442 indexed citations breakdown →

15.

Flinn, Ian W., Marshall T. Schreeder, Nina D. Wagner‐Johnston, et al.. (2010). A Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Combination with Rituximab and/or Bendamustine In Patients with Relapsed or Refractory B-Cell Malignancies.. Blood. 116(21). 2832–2832. 16 indexed citations

16.

Rajfer, Jacob, Philip J. Aliotta, Christopher P. Steidle, et al.. (2006). Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. International Journal of Impotence Research. 19(1). 95–103. 84 indexed citations

17.

Seftel, A D, James Fletcher, M C Deeley, et al.. (2005). A three-part study to investigate the incidence and potential etiologies of tadalafil-associated back pain or myalgia. International Journal of Impotence Research. 17(5). 455–461. 9 indexed citations

18.

Rusnak, James M., Stephen L. Kopecky, Ian P. Clements, et al.. (2001). An anti-CD11/CD18 monoclonal antibody in patients with acute myocardial infarction having percutaneous transluminal coronary angioplasty (the FESTIVAL study). The American Journal of Cardiology. 88(5). 482–487. 56 indexed citations

19.

Henig, Noreen, et al.. (2000). Effect of Recombinant Human Platelet-activating Factor-Acetylhydrolase on Allergen-induced Asthmatic Responses. American Journal of Respiratory and Critical Care Medicine. 162(2). 523–527. 51 indexed citations

20.

Bowen, James D., et al.. (1998). Phase I study of a humanized anti-CD11/CD18 monoclonal antibody in multiple sclerosis*. Clinical Pharmacology & Therapeutics. 64(3). 339–346. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact